Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | MRE11 | P49959 | 9/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13556405 | 0.89 | XIAP (0.48) | TYRLMNAXIAPMRE11OPRK1 | |
| SCHEMBL3429639 | 0.87 | TYR (0.46) | TYRLMNAXIAPMRE11OPRK1 | |
| SCHEMBL10266220 | 0.87 | TYR (0.51) | TYRLMNAMRE11MEN1KMT2A | |
| SCHEMBL3429515 | 0.86 | TYR (0.45) | TYRLMNAXIAPOPRK1ATM | |
| SCHEMBL9890985 | 0.85 | TYR (0.50) | TYRLMNAXIAPATMMEN1 | |
| SCHEMBL9890978 | 0.82 | TYR (0.42) | TYRLMNAMRE11OPRK1ATM | |
| SCHEMBL9890980 | 0.82 | KCNQ1 (0.42) | TYRLMNAXIAPMRE11OPRK1 | |
| SCHEMBL22110048 | 0.81 | ALDH1A1 (0.47) | TYRLMNAXIAPMEN1KMT2A | |
| SCHEMBL7921060 | 0.79 | TYR (0.51) | TYRLMNAMRE11MEN1NPC1 | |
| SCHEMBL10266218 | 0.78 | ALDH1A1 (0.48) | TYRLMNAMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142929-A1 | PROCESS FOR PREPARING SULFONYL QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142929-A1 | PROCESS FOR PREPARING SULFONYL QUINOLINES | GYS2, CYP3A7, GBA1 | TYR 1100/4885LMNA 2710/4885XIAP 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.